- Home
- BCH vs SNN Comparison
BCH vs SNN Comparison
Compare BCH & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCH
- SNN
- Stock Information
- Founded
- BCH 1893
- SNN 1856
- Country
- BCH Chile
- SNN United Kingdom
- Employees
- BCH N/A
- SNN N/A
- Industry
- BCH Commercial Banks
- SNN Industrial Specialties
- Sector
- BCH Finance
- SNN Health Care
- Exchange
- BCH Nasdaq
- SNN Nasdaq
- Market Cap
- BCH 12.5B
- SNN 11.1B
- IPO Year
- BCH 2002
- SNN 1999
- Fundamental
- Price
- BCH $25.30
- SNN $26.16
- Analyst Decision
- BCH Hold
- SNN Strong Buy
- Analyst Count
- BCH 1
- SNN 1
- Target Price
- BCH $23.00
- SNN N/A
- AVG Volume (30 Days)
- BCH 175.8K
- SNN 837.8K
- Earning Date
- BCH 02-12-2025
- SNN 02-25-2025
- Dividend Yield
- BCH 6.73%
- SNN 2.91%
- EPS Growth
- BCH N/A
- SNN 39.77
- EPS
- BCH 0.01
- SNN 0.35
- Revenue
- BCH $2,675,332,916.00
- SNN $5,642,000,000.00
- Revenue This Year
- BCH N/A
- SNN $6.24
- Revenue Next Year
- BCH $5.35
- SNN $4.92
- P/E Ratio
- BCH $10.36
- SNN $36.99
- Revenue Growth
- BCH N/A
- SNN 5.48
- 52 Week Low
- BCH $20.93
- SNN $23.65
- 52 Week High
- BCH $25.97
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- BCH 71.32
- SNN 61.68
- Support Level
- BCH $24.25
- SNN $25.20
- Resistance Level
- BCH $25.08
- SNN $25.85
- Average True Range (ATR)
- BCH 0.38
- SNN 0.45
- MACD
- BCH 0.13
- SNN 0.10
- Stochastic Oscillator
- BCH 99.04
- SNN 51.90
About BCH Banco De Chile ADS
Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile) Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.